VP is a benzoporphyrin derivative that inhibits the nuclear YAP/TAZ-TEAD interaction to suppress the transcriptional activity, which is an FDA-approved drug for the treatment of choroidal neovascularization and is commonly used as a YAP/TAZ inhibitor [41, 42]. Here, YAP1 is linked to choroidal neovascularization.